It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Eukaryotic cells employ the ribosome-associated quality control complex (RQC) to maintain homeostasis despite defects that cause ribosomes to stall. The RQC comprises the E3 ubiquitin ligase Ltn1p, the ATPase Cdc48p, Rqc1p, and Rqc2p. Upon ribosome stalling and splitting, the RQC assembles on the 60S species containing unreleased peptidyl-tRNA (60S:peptidyl–tRNA). Ltn1p and Rqc1p facilitate ubiquitination of the incomplete nascent chain, marking it for degradation. Rqc2p stabilizes Ltn1p on the 60S and recruits charged tRNAs to the 60S to catalyze elongation of the nascent protein with carboxy-terminal alanine and threonine extensions (CAT tails). By mobilizing the nascent chain, CAT tailing can expose lysine residues that are hidden in the exit tunnel, thereby supporting efficient ubiquitination. If the ubiquitin–proteasome system is overwhelmed or unavailable, CAT-tailed nascent chains can aggregate in the cytosol or within organelles like mitochondria. Here we identify Vms1p as a tRNA hydrolase that releases stalled polypeptides engaged by the RQC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Howard Hughes Medical Institute, Chevy Chase, MD, USA; Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA
2 Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA
3 Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA; California Institute for Quantitative Biomedical Research, San Francisco, CA, USA
4 Molecular Medicine Program, University of Utah, Salt Lake City, UT, USA
5 Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA; California Institute for Quantitative Biomedical Research, San Francisco, CA, USA
6 Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA
7 Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA; California Institute for Quantitative Biomedical Research, San Francisco, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA